Valuation: Santen Pharmaceutical Co., Ltd.

Market Cap 539B 3.41B 3.04B 2.84B 2.58B 4.86B 329B 4.89B 34.12B 13.33B 168B 12.79B 12.51B P/E 2027 *
13.9x
P/E 2028 * 12.4x
Enterprise Value 492B 3.11B 2.78B 2.59B 2.36B 4.44B 301B 4.47B 31.16B 12.17B 153B 11.68B 11.42B EV / Sales 2027 *
1.62x
EV / Sales 2028 * 1.48x
Free-Float
96.88%
Yield 2027 *
2.48%
Yield 2028 * 2.79%
1 week-1.06%
Current month-1.06%
1 month-5.58%
3 months-20.51%
6 months-8.82%
Current year+6.90%
1 week 9.1
Extreme 9.1
9.45
1 month 9.1
Extreme 9.1
9.9
3 years 7.8
Extreme 7.8
12
5 years 6.4
Extreme 6.4
12.7
Manager TitleAgeSince
Chief Executive Officer 67 01/09/2022
Director of Finance/CFO - -
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 67 23/06/2017
Director/Board Member 45 01/06/2024
Director/Board Member 48 01/06/2024
Change 5-day change 1-year change 3-year change Capi.($)
+2.15%-1.06%+5.08%+8.77% 3.41B
+2.70%+2.73%+40.91%+110.31% 1,060B
+1.44%-2.38%+36.83%+63.95% 623B
+1.75%+3.73%+16.55%+83.05% 480B
+0.60%-1.73%+62.98%+37.46% 352B
-1.50%+1.43%+21.52%+41.12% 345B
-0.81%+0.63%+11.55%+34.80% 274B
-0.53%-1.71%-5.56%+11.18% 249B
+2.60%-2.00%+39.77%+54.44% 223B
+1.82%-1.48%+25.75%+96.48% 182B
Average +0.32%-0.48%+25.54%+54.16% 420.89B
Weighted average by Cap. +0.00%+0.04%+31.44%+70.16%

Financials

2027 *2028 *
Net sales 304B 1.92B 1.72B 1.6B 1.46B 2.74B 186B 2.76B 19.26B 7.52B 94.58B 7.22B 7.06B 313B 1.98B 1.77B 1.65B 1.5B 2.82B 191B 2.84B 19.81B 7.74B 97.27B 7.42B 7.26B
Net income 38.22B 242M 216M 201M 183M 345M 23.38B 347M 2.42B 946M 11.89B 907M 888M 40.85B 258M 231M 215M 196M 368M 24.98B 371M 2.59B 1.01B 12.71B 970M 949M
Net Debt -46.74B -296M -264M -246M -224M -421M -28.59B -425M -2.96B -1.16B -14.54B -1.11B -1.09B -75.89B -480M -429M -400M -363M -684M -46.42B -689M -4.81B -1.88B -23.61B -1.8B -1.76B
Projected Income Statement - Annual - Santen Pharmaceutical Co., Ltd.
Logo Santen Pharmaceutical Co., Ltd.
Santen Pharmaceutical Co Ltd is a Japan-based company mainly engaged in the research and development, manufacture, and sale of pharmaceuticals. The Company engages in global research and development, manufacture, sale, and marketing of pharmaceuticals in the ophthalmology field. The Company engages in prescription pharmaceuticals, over-the-counter pharmaceuticals, medical devices, and other businesses. The Company operates in Japan, Asia, Europe, the Middle East, and Africa (EMEA), China, and other regions.
Employees
-
Date Price Change
08/10/26 €9.400 +1.08%
07/10/26 €9.300 0.00%
06/10/26 €9.300 +0.54%
05/10/26 €9.250 -1.60%
02/10/26 €9.400 +0.53%
Trader
Investor
Global
Quality
ESG MSCI
BBB
Ratings Surperformance© - Santen Pharmaceutical Co., Ltd.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
1,677.00JPY
Average target price
2,377.78JPY
Spread / Average Target
+41.79%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Santen Pharmaceutical Co., Ltd.